Surrozen SRZN Stock
Surrozen Price Chart
Surrozen SRZN Financial and Trading Overview
| Surrozen stock price | 9.8 USD |
| Previous Close | 0.64 USD |
| Open | 0.66 USD |
| Bid | 0 USD x 3100 |
| Ask | 0 USD x 800 |
| Day's Range | 0.62 - 0.66 USD |
| 52 Week Range | 0.34 - 3.65 USD |
| Volume | 44.91K USD |
| Avg. Volume | 118.65K USD |
| Market Cap | 19.85M USD |
| Beta (5Y Monthly) | -0.325617 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -21.67 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 USD |
SRZN Valuation Measures
| Enterprise Value | -37276904 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1785715 |
| PEG Ratio (5 yr expected) | -0.01 |
| Price/Sales (ttm) | 1.5881871 |
| Price/Book (mrq) | 0.31488553 |
| Enterprise Value/Revenue | -2.982 |
| Enterprise Value/EBITDA | 0.902 |
Trading Information
Surrozen Stock Price History
| Beta (5Y Monthly) | -0.325617 |
| 52-Week Change | -72.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.65 USD |
| 52 Week Low | 0.34 USD |
| 50-Day Moving Average | 0.63 USD |
| 200-Day Moving Average | 1.13 USD |
SRZN Share Statistics
| Avg. Volume (3 month) | 118.65K USD |
| Avg. Daily Volume (10-Days) | 61.17K USD |
| Shares Outstanding | 30.08M |
| Float | 18.37M |
| Short Ratio | 2.84 |
| % Held by Insiders | 8.16% |
| % Held by Institutions | 66.10% |
| Shares Short | 229.86K |
| Short % of Float | 1.12% |
| Short % of Shares Outstanding | 0.76% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -345.84% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.16% |
| Return on Equity (ttm) | -51.12% |
Income Statement
| Revenue (ttm) | 12.5M USD |
| Revenue Per Share (ttm) | 0.37 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -41328000 USD |
| Net Income Avi to Common (ttm) | -42354000 USD |
| Diluted EPS (ttm) | -1.33 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 61.75M USD |
| Total Cash Per Share (mrq) | 2.05 USD |
| Total Debt (mrq) | 5.08M USD |
| Total Debt/Equity (mrq) | 8.05 USD |
| Current Ratio (mrq) | 8.606 |
| Book Value Per Share (mrq) | 2.096 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -39941000 USD |
| Levered Free Cash Flow (ttm) | -23617376 USD |
Profile of Surrozen
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 171 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | (650) 489-9000 |
| Website | https://www.surrozen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 74 |
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Q&A For Surrozen Stock
What is a current SRZN stock price?
Surrozen SRZN stock price today per share is 9.8 USD.
How to purchase Surrozen stock?
You can buy SRZN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Surrozen?
The stock symbol or ticker of Surrozen is SRZN.
Which industry does the Surrozen company belong to?
The Surrozen industry is Biotechnology.
How many shares does Surrozen have in circulation?
The max supply of Surrozen shares is 3.28M.
What is Surrozen Price to Earnings Ratio (PE Ratio)?
Surrozen PE Ratio is now.
What was Surrozen earnings per share over the trailing 12 months (TTM)?
Surrozen EPS is -21.67 USD over the trailing 12 months.
Which sector does the Surrozen company belong to?
The Surrozen sector is Healthcare.
Surrozen SRZN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
| NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}